3F8 + GM-CSF + isotretinoin

This is a combination therapy used primarily for the consolidation treatment of high-risk neuroblastoma in pediatric patients who have achieved first or subsequent complete remission (CR) or very good partial remission (VGPR). The regimen consists of: - **Anti-GD2 monoclonal antibody 3F8** (murine IgG3 or its humanized form hu3F8/naxitamab), which targets the GD2 disialoganglioside antigen highly expressed on neuroblastoma cells. The antibody mediates tumor cell killing through mechanisms such as complement-dependent cytotoxicity (CDC) and especially antibody-dependent cell-mediated cytotoxicity (ADCC), engaging immune effector cells like granulocytes and monocytes. - **Granulocyte-macrophage colony-stimulating factor (GM-CSF)**, a cytokine that enhances the number and activation state of granulocytes and macrophages, thereby amplifying ADCC mediated by anti-GD2 antibodies. - **Isotretinoin** (13-cis-retinoic acid), a retinoid that induces differentiation in neuroblastoma cells to reduce minimal residual disease. The combination is designed to maximize immune-mediated clearance of residual tumor after intensive chemotherapy. Clinical studies have shown improved event-free survival when this immunotherapy is added to standard post-consolidation care[1][2][5][7][9].

Brand names

LeukineAccutane

Other names

anti-GD2 monoclonal antibody 3F8 with GM-CSF and isotretinoinanti-GD-2 monoclonal antibody 3F8 with GM-CSF and isotretinoinanti-GD 2 monoclonal antibody 3F8 with GM-CSF and isotretinoinnaxitamab (hu3F8) with GM-CSF and isotretinoin